Supernus Pharmaceuticals Inc (SUPN) - Total Liabilities
Based on the latest financial reports, Supernus Pharmaceuticals Inc (SUPN) has total liabilities worth $396.88 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Supernus Pharmaceuticals Inc (SUPN) long-term investment share to see how much of total assets are deployed in long-term investments.
Supernus Pharmaceuticals Inc - Total Liabilities Trend (2008–2025)
This chart illustrates how Supernus Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see SUPN asset base.
Supernus Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Supernus Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr2.08 Billion |
|
Newell Brands Inc
NASDAQ:NWL
|
USA | $8.61 Billion |
|
CNNC Hua Yuan Titanium Dioxide Co Ltd
SHE:002145
|
China | CN¥7.41 Billion |
|
Central Puerto S.A.
BA:CEPU
|
Argentina | AR$1.25 Trillion |
|
NewAmsterdam Pharma Company N.V. Ordinary Shares
NASDAQ:NAMS
|
USA | $58.36 Million |
|
Beam Therapeutics Inc
NASDAQ:BEAM
|
USA | $319.19 Million |
|
Bure Equity AB
ST:BURE
|
Sweden | Skr19.00 Million |
|
Maple Leaf Foods Inc.
TO:MFI
|
Canada | CA$2.81 Billion |
Liability Composition Analysis (2008–2025)
This chart breaks down Supernus Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Supernus Pharmaceuticals Inc (SUPN) balance sheet quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.08 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Supernus Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Supernus Pharmaceuticals Inc (2008–2025)
The table below shows the annual total liabilities of Supernus Pharmaceuticals Inc from 2008 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $390.93 Million | +17.63% |
| 2024-12-31 | $332.34 Million | -6.69% |
| 2023-12-31 | $356.16 Million | -56.37% |
| 2022-12-31 | $816.30 Million | -6.53% |
| 2021-12-31 | $873.30 Million | +15.02% |
| 2020-12-31 | $759.24 Million | +34.41% |
| 2019-12-31 | $564.85 Million | +7.63% |
| 2018-12-31 | $524.79 Million | +234.29% |
| 2017-12-31 | $156.98 Million | +33.25% |
| 2016-12-31 | $117.81 Million | +68.65% |
| 2015-12-31 | $69.86 Million | +5.59% |
| 2014-12-31 | $66.15 Million | -14.67% |
| 2013-12-31 | $77.53 Million | +112.89% |
| 2012-12-31 | $36.42 Million | -17.77% |
| 2011-12-31 | $44.29 Million | -51.51% |
| 2010-12-31 | $91.33 Million | +6.13% |
| 2009-12-31 | $86.06 Million | +2.59% |
| 2008-12-31 | $83.88 Million | -- |
About Supernus Pharmaceuticals Inc
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with P… Read more